🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in London

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2846 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 19 Sep 2026, 04:26 UTC
2846
Studies in scope
industry-sponsored, all four open statuses
1377
Recruiting now
open to new participants
539
Lead sponsors
across recruiting studies
Top sites
London 20 Birmingham 10 Manchester 8 Glasgow 7 Sutton 6
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca136 Merck Sharp & Dohme LLC99 Hoffmann-La Roche80 Janssen Research & Development, LLC73 Novartis Pharmaceuticals72 Clear sponsor filter
Site city
London20 Birmingham10 Manchester8 Glasgow7 Sutton6
All 41 cities
Target enrolment
to
20 of 2846 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
NCT07213674Metastatic Castration-resistant Prostate Cancer
Amgen
Phase 3
750
London, Sutton
2025-11-28
Recruiting
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
NCT07094113KRAS Altered Advanced or Metastatic Solid Tumors
Amgen
Phase 1
434
London, Sutton
2025-07-31
Recruiting
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
NCT06747949Sjögren's Syndrome
Amgen
Phase 3
844
Portsmouth, Leeds, London
2025-02-25
Active, closed
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
NCT06691984Metastatic Castration-resistant Prostate Cancer
Amgen
Phase 3
707
Glasgow, London, Sutton
2024-12-09
Active, closed
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
NCT06637371Asthma
Amgen
Phase 1
21
Cambridge, London, Manchester
2024-10-16
Recruiting
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
NCT06252649Metastatic Colorectal Cancer
Amgen
Phase 3
450
Birmingham, Glasgow, London, Maidstone, Northwood, Sheffield, Sutton
2024-07-17
Active, closed
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease
NCT06248619Thyroid Eye Disease
Amgen
Phase 3
89
London
2024-07-05
Active, closed
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
NCT06360354Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
Amgen
Phase 1
120
Birmingham, London
2024-05-29
Active, closed
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
NCT06245408Sjögren's Syndrome (SS)
Amgen
Phase 3
434
Leeds, London
2024-04-08
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
Amgen
Phase 3
404
London, Manchester
2024-02-20
Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356Non-Small Cell Lung Cancer (NSCLC)
Amgen
Phase 3
750
Birmingham, Inverness, London, Northwood, Nottingham, Sutton, Torquay, Truro
2023-11-16
Recruiting
Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
NCT05549258Neuromyelitis Optica Spectrum Disorder
Amgen
Phase 2
15
London, Birmingham
2023-07-03
Active, closed
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
NCT05740566Small Cell Lung Cancer (SCLC)
Amgen
Phase 3
509
London, Manchester
2023-05-31
Active, closed
A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
NCT05094336Advanced MTAP-null Solid Tumors
Amgen
Phase 1/2
329
London, Sutton
2022-02-01
Active, closed
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
NCT05060016Relapsed/Refractory Small Cell Lung Cancer
Amgen
Phase 2
222
London, Manchester
2021-12-01
Active, closed
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
NCT04994717Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Amgen
Phase 3
303
London
2021-11-02
Active, closed
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
NCT04540497IgG4 Related Disease
Amgen
Phase 3
135
Leeds, London, Newcastle, Oxford
2020-12-04
Recruiting
A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis
NCT03969329Secondary Hyperparathyroidism
Amgen
Phase 3
24
Glasgow, Leeds, London, Southampton
2019-12-20
Active, closed
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
NCT04185883Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
Amgen
Phase 1
610
London
2019-12-17
Active, closed
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
NCT03836040Migraine
Amgen
Phase 3
457
Cardiff, Glasgow, Liverpool, London, Manchester, Oxford
2019-07-19
Rows per page Showing 1–20 of 20
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-uk/city/london

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.